Introduction
============

The definition of "elderly" is controversial. The traditional demographic definitions include those patients exceeding 65 years of age. Census statistics show that this age group is expected to rise. Agreement on what constitutes the elderly cancer patient is particularly vital since the community age structure is very dynamic ([@b75-cia-0103-221]). Functional deterioration is more frequently apparent beyond the age of 70 years ([@b84-cia-0103-221]). No two elderly individuals are same: they differ in their physical fitness, cognitive level, and presence of co-morbidities, quality of life, and life expectations. Surprisingly, few objective instruments have been made available to categorise age-related pre-existing chronic illness; age related functional physical decline, or preoperative risk status ([@b22-cia-0103-221]; [@b84-cia-0103-221]; [@b58-cia-0103-221]).

Ageism is defined as a "prejudice towards, stereotyping of and/or discrimination against any person or persons directly and solely as a function of their having attained a chronological age which the social group defines as old" ([@b3-cia-0103-221]). Ageism attitudes are deep-rooted in mankind and are reflected in language, attitude, beliefs, behaviours, and policies ([@b61-cia-0103-221]). Healthcare providers, including surgeons, are no exception to ageist bias. Age frequently affects the overall cancer treatment plan, including the surgeon's view towards operative strategy and multi-modal treatment ([@b58-cia-0103-221]). The majority of surgical oncologists seem to be aware of the burden of elderly patients affected by cancer and are not biased by an ageist approach. However there is disturbing evidence of a wide variety of treatment options offered, ranging from a minimalist approach to over-treatment ([@b4-cia-0103-221]).

Cancer is a disease of the aging. Solid tumors predominantly affect the aged and most cancer-related deaths occur within this age group ([@b15-cia-0103-221]; [@b80-cia-0103-221]; [@b1-cia-0103-221]). The elderly receive substandard cancer treatment in comparison with the young although the quoted reasons are many ([@b82-cia-0103-221]; [@b39-cia-0103-221]; [@b14-cia-0103-221]; [@b38-cia-0103-221]; [@b68-cia-0103-221]; [@b16-cia-0103-221]; [@b33-cia-0103-221]; [@b34-cia-0103-221]; [@b4-cia-0103-221]). This has prompted several surgical oncologists to review their series. Outcomes of these are superimposable long-term cancer-related outcome across all age groups and short term complications and mortality which do not seem to differ in a highly selected patient group undergoing cancer surgery ([@b78-cia-0103-221]; [@b34-cia-0103-221]).

Surgery for elderly cardiac, orthopaedic, and vascular diseases is increasingly accepted. Yet, the reluctance to offer optimal cancer surgery continues ([@b1-cia-0103-221]) although it remains the primary treatment for solid cancer ([@b80-cia-0103-221]). Our limited knowledge of the elderly sub-population is due to the exclusion of onco-geriatric patients from clinical trials ([@b16-cia-0103-221]; [@b33-cia-0103-221]; [@b34-cia-0103-221]). There is an urgent need for expanding our understanding of cancer behavior and cancer management for this unique group. Better understanding will come with elderly patients taking part in clinical research and by encouraging clinicians to take part in scientific meetings dedicated to onco-geriatrics.

Epidemiology
============

The median life expectancy of population among industrialized countries has dramatically expanded in recent years. An effect of an absolute rise in geriatric population among populous countries (ie, China, India, and Brazil) despite smaller in proportion (11% to 15%), and a higher proportionate rise (20%) in developed countries by 2020, is likely to lead to geriatric population explosion ([@b25-cia-0103-221]; [@b77-cia-0103-221]; [@b45-cia-0103-221]). At the end of the 19th century, the average life expectancy was 40 years, but has now doubled to 81 years of expected survival for females, and 76 years for males in the UK. A 60 year old subject is now expected to survive for 24 years and an 80 year old is expected to survive for 6 years in Western Europe ([@b50-cia-0103-221]). On the other hand, the risk of developing cancer increases with age. According to the Cancer Incidence, Mortality and Prevalence in the European Union (EUCAN) 90 data, 58% of cancers, and 69% of cancer deaths, affect subjects aged 65 years or more. When all tumors are taken into account, the risk of developing cancer among persons older than 65 is 2.9-fold for males and 2.2-fold for females, in comparison with 55 to 64 year olds ([@b20-cia-0103-221]). According to the SEER (Surveillance Epidemiology and End Results) data, the prevalence of cancer is 207.4 cases/100 000 in the \<65 year old subjects, and 2163.9/100 000 in ≥65 year old subjects in the US. Mortality in this survey was 68.8 and 1076.2/100 000 subjects, respectively. This means cancer prevalence is 10 times, and mortality 15 times higher in the ≥65 year olds ([@b50-cia-0103-221]).

[@b42-cia-0103-221] concluded the methodological quality of randomized controlled trials (RCT) in very elderly subjects is equivalent to that of RCT in the general adult population. Nevertheless, RCT are very scarce and neglect certain diseases. RCT in elderly should be strongly encouraged ([@b42-cia-0103-221]). Since only a small sub-setting of geriatric patients are being entered into clinical trials ([@b27-cia-0103-221], [@b26-cia-0103-221], [@b28-cia-0103-221]; [@b13-cia-0103-221]), elderly patients are still being managed on the assumptions and outcomes derived from a younger cancer patient.

Despite this epidemiological "time bomb" ([@b55-cia-0103-221]; [@b66-cia-0103-221]), there is concern that the scientific community has so far been unable to develop a significant amount of evidence-based knowledge.

Tumor biology
=============

The increase in incidence of cancer with age is related to a number of biologic factors. Age-related etiological factors includes decreased immune surveillance, longer duration of carcinogenic exposure, increased susceptibility of cells to carcinogens, decreased DNA repair, oncogene activation or amplification, and defects in tumor-suppressor genes. The biological behaviour of neoplasm, once initiated, may vary in different age groups depending on tumour type, immune system status, and alterations in other regulatory factors such as angiogenesis. Attention to age-related biological changes are essential to the designing of successful therapy ([@b21-cia-0103-221]).

The biology of cancers differs in various age groups, with variations in growth patterns, and doubling times, intrinsic hormonal receptor expression, DNA ploidy, tumor angiogenesis, percentage of cells in S-phase, p53 expression, and extracellular matrix protein expression ([@b62-cia-0103-221]; [@b24-cia-0103-221]; [@b23-cia-0103-221]; [@b60-cia-0103-221]). The microenvironment of senescent tissue is less capable of supporting rapid tumor growth. Histologically identical tumor in older patients may behave differently ([@b59-cia-0103-221]; [@b41-cia-0103-221]; [@b31-cia-0103-221]; [@b2-cia-0103-221]). The subcellular changes involved in the aging process and the effect of particular aging 'phenotype' has on cancer susceptibility is ill-understood ([@b76-cia-0103-221]; [@b53-cia-0103-221]). The correlation between immune system and cancer development/progression are currently poorly understood ([@b53-cia-0103-221]; [@b69-cia-0103-221]; [@b85-cia-0103-221]). Prolonged tumor-associated antigen exposure associated with immune 'exhaustion' and absence of repair genes is the predominance of a 'frail' gene variant ([@b12-cia-0103-221]; [@b36-cia-0103-221]; [@b53-cia-0103-221]).

Age influences the predilection of cancer for disease site and histology type, ie, higher incidence of adeno-carcinoma of the distal esophagus, well-differentiated gastric tumors, right-sided colonic cancer, and low-grade lobular or mucinous type breast tumors in the elderly population have been reported ([@b5-cia-0103-221]). Similarly a higher incidence of larger thyroidal tumour with Hürthle cell variant, extra-thyroidal growth and metastases at presentation are noted in elderly ([@b9-cia-0103-221]). Elderly patients have greater frequency of tumors with more indolent histology and an overall favorable tumor profile (Hayman and Muss 2003): Older women with breast cancer tend to have more estrogen receptor-positive tumors ([@b83-cia-0103-221]). These basic pathological differences will inherently affect outcome ([@b36-cia-0103-221]). For most types of solid epithelial tumors, old age itself does not appear to function as an independently negative prognostic variable for cancer-specific survival; a finding evident in recent studies assessing colorectal cancer ([@b5-cia-0103-221]; [@b73-cia-0103-221]; [@b18-cia-0103-221]), gastric cancer ([@b54-cia-0103-221]; [@b46-cia-0103-221]), esophageal carcinoma ([@b44-cia-0103-221]; [@b63-cia-0103-221]), liver ([@b19-cia-0103-221]), head & neck ([@b67-cia-0103-221]; [@b65-cia-0103-221]) and breast cancers ([@b79-cia-0103-221]; [@b30-cia-0103-221]; [@b57-cia-0103-221]; [@b71-cia-0103-221]).

More complex issues, however, impact on different age groups and affect their overall and disease-free survival.

Surgical risk assessment
========================

The most important responsibility a surgeon is asked to take is to decide whether to operate or not ([@b43-cia-0103-221]; [@b29-cia-0103-221]). This is particularly true when the patient is a high surgical risk.

The decision-making process is complex in a poor surgical candidate or frail and elderly: on one side, a nihilistic approach has been repeatedly reported, which results in intolerably poor cancer management and outcomes; on the other, the surgical oncologist must balance the operative risk against benefits.

A number of factors, including a greater need for information, a more effective utilization of available resources, and advances in peri-operative management and surgical techniques, demand an improved risk definition to be shared between the surgeon and the patient.

Unfortunately there seems to be no laboratory test capable of predicting postoperative adverse outcomes ([@b10-cia-0103-221]).

None of the risk classifications aimed at predicting outcomes in specific conditions used by surgeons are completely reliable. More importantly, no scoring method has ever been attempted specifically in the elderly population and a "CGA-snap-shot" of senior patients undergoing surgery has never been attempted.

The recommendations of the consensus meeting held during the 6th International Conference on Geriatric Oncology ([@b10-cia-0103-221]) was that any elderly cancer patient should firstly be assessed on his/her frailty, and then considered for appropriate cancer management. We consecutively endeavor on holistic assessment of this cancer sub-setting.

Currently available risk assessment tools include American Society of Anesthesiologists (ASA) scoring system. The ASA scoring system does not measure operative risk, rather it globally assess the degree of sickness or physical state prior to anesthesia and surgery.

Sensitivity of ASA scoring to differentiate the proportion of patients belonging to ASA II vs III ([@b52-cia-0103-221]), where both groups show a similar mortality under elective conditions (15%) is poor.

The assessment of cardiac risk is addressed by the Goldman Cardiac Risk Index (CRI) ([@b37-cia-0103-221]); an instrument designed to assess cardiac risk in noncardiac surgery but is rarely used by surgeons ([@b56-cia-0103-221]). Respiratory complications were analyzed by [@b49-cia-0103-221] who identified the following as associated with postoperative respiratory complications: 1) age over 70; 2) peri-operative broncho-dilator use; 3) abnormal chest x-ray; and 4) high ASA grade. Lawrence et al (1994) identified four preoperative variables that were associated with postoperative respiratory complications: 1) abnormal respiratory examination; 2) abnormal chest x-ray; 3) Goldman CRI; and 4) the Charlson co-morbidity index ([@b17-cia-0103-221]). These have not been formalized as a score or validated.

The Acute Physiological and Chronic Health Evaluation (APACHE) is the best known physiological scoring system ([@b48-cia-0103-221]). It is based on 34 physiological variables taking the worst values in the first 24 hours from the patient's admission to an intensive care unit (ICU). Various modifications of this APACHE system are now available: APACHE II ([@b47-cia-0103-221]) uses 12 physiological variables; it is currently being used in general and surgical intensive care patients. Its application in the ICU seems very appropriate, but its utility to general surgical patients who may not require respiratory support in the ICU is limited.

A relatively popular risk assessment tool especially in UK is POSSUM (Physiological and Operative Severity Score for EnUmaration of Mortality and Morbidity) as well as Portsmouth modification (P-POSSUM) ([@b64-cia-0103-221]). The weakness of the tool is to overestimate mortality rate for low risk procedures, inability to predict postoperative outcome in preoperative setting and is affected by surgeon dependent factors rather than intrinsic difficulty of the case ([@b11-cia-0103-221]; [@b74-cia-0103-221]). Age is an independent risk factor built into above mentioned risk prediction tools.

Preoperative Assessment of Cancer in Elderly (PACE)
===================================================

PACE is a prospective multicenter, international cooperative investigation which aims at defining the general health condition of onco-geriatric surgical candidates. PACE is designed to assess the functional activities of geriatric patient and hence to assess the functional life of an onco-geriatric patient. We propose this will help in predicting the individualized risk of cancer surgery. The pilot study has proven PACE is feasible, inexpensive and well accepted by the patient ([@b81-cia-0103-221]). Our study population constituted of ≥70 years age patients undergoing moderate, major and major + elective cancer surgery whose Mini Mental Score is ≥18 (ability to give written informed consent). The end points of the study are 30 days morbidity, 30 days mortality, and hospital bed days. The aim is to predict preoperatively the probable outcome of cancer surgery treatment in elderly. The tools incorporated in the PACE are detailed in Table [1](#t1-cia-0103-221){ref-type="table"}.

Results
=======

213 patients were prospectively recruited for the study from July 2003 to September 2004. The postoperative outcome is assessed using a morbidity checklist (Table [2](#t2-cia-0103-221){ref-type="table"}). The interim analysis results (Table [3](#t3-cia-0103-221){ref-type="table"}) show median age was 76 years (70--100 years). Postoperative complications were noted in 64 (30%). The median number of co-morbidity was 2 in complications group and 1 in complications-free group. Functional assessment using performance status (PS), (p\<0.0001) and activities of daily living (ADL) (p\<0.005) achieved statistical significance in predicting postoperative morbidity. Aspects of PACE relating to psychological well being (Geriatric Depression Score, Mini Mental State) do not appear to be significantly associated with post operative morbidity. The number of co-morbidities, ASA, instrumental activities of daily living (IADL) which failed to achieve statistical significance will be a reassessed on a larger sample. Recruitment to the study is currently ongoing and full results will be revealed on completion.

How to improve our understanding of elderly cancer patients?
============================================================

It is estimated that up to a third of cancer deaths is preventable by the promotion of education. An emphasis should be on the dangers of a delayed diagnosis, as well as the erroneous interpretation of misleading symptoms in the presence of co-morbidities ([@b6-cia-0103-221]). Educational endeavours for elderly should target specialists and general practitioners alike. Optimizing management of cancer in elderly requires better understanding. This could be achieved by encouraging elderly to take part into clinical trials specifically developed for onco-geriatric series. Elderly cancer patients should be encouraged to enroll with the same vigor as their younger counterpart. Elderly wish to participate in trials in contrast to present perceptions ([@b70-cia-0103-221]). It is also desirable to make cancer management decision within a dedicated multidisciplinary (MDT) meeting, comprising of onco-surgeon, oncologist, radiation therapist, geriatricians, anesthesiologists with interest in geriatric surgery, and other support staff involved in elderly patient care. Educational opportunities like International Society of Geriatrics Oncology (SIOG 2006) conferences and the European School of Oncology ([@b32-cia-0103-221]) courses should be utilized to enhance our knowledge and to discuss issues pertaining to management of elderly cancer. Further learning modules should be included in the medical curriculum in order to learn to look beyond age.

Conclusions
===========

An increase in elderly surgical cancer workload is inevitable in the coming years. The special needs of elderly cancer patient should be taken into consideration prior to treatment planning. Provision of care should honor patients' preferences across all age groups. More progress in optimization of surgery for cancer in elderly could be achieved with the availability of validated tools capable of predicting postoperative outcomes. Clinical trials should be specifically developed for onco-geriatric series and elderly cancer patients should be encouraged to enroll. A multidisciplinary approach is the way forward. Educational opportunities like SIOG and ESO should be utilized to enhance our understanding of this unique subgroup. Learning modules should be created to look beyond age in cancer treatment planning. Developments in the surgery and expansion of our elderly cancer knowledge base are the way forward to optimize cancer surgery for elderly.

###### 

Validated instruments used with PACE

  ------------------------------------------------------------------------------------------------
  Mini Mental State Examination (MMS)
  Satariano's Modified Index of Comorbidities
  Activities of Daily Living (ADL)
  Instrumental Activities of Daily Living (IADL)
  Geriatric Depression Scale (GDS)
  Brief Fatigue Inventory (BFI)
  Eastern Co-operative Oncology Group Performance Status (PS)
  American Society of Anesthesiologists Physical Status (ASA)
  Physiological and Operative Severity Score for EnUmeration of Mortality and Morbidity (POSSUM)
  Portsmouth POSSUM Modification (P-POSSUM)
  ------------------------------------------------------------------------------------------------

**Abbreviations:** PACE, Preoperative Assessment of Cancer in Elderly.

###### 

30 days morbidity check

  **Complications**
  ------------------------------
  Respiratory
  Cardiac failure
  Renal failure
  Generalized sepsis
  Stroke/Neurological problems
  Hemorrhage and bleeding
  Nutritional problems
  Other organ failure
  Wound infection/dehiscence
  Thromboembolic problems
  Hepatic failure
  Urinary retention
  Anastomotic failure
  Peripheral ischemia
  Endocrine failure
  Pressure sores
  Analgesic problems
  Others

###### 

PACE Interim analysis: association of PACE with postoperative morbidity

  **Components**               **Complications (64 patients)**   **No Complications (149 patients)**   **p**
  ---------------------------- --------------------------------- ------------------------------------- ----------
  **Median (IQR)**                                                                                     
  Comorbidities                2 (0--3)                          1 (0--2)                              0.024
  MMS                          28 (27--30)                       28 (26--30)                           0.917
  GDS                          3 (1--6)                          2 (1--4)                              0.018
  BFI                          2.2 (0.2--4.4)                    1.2 (0--4.4)                          0.156
  **Number of patients (%)**                                                                           
  PS = 0                       30 (46.9)                         122 (81.9)                            \<0.0001
  ADL (Dependent)              38 (59.4)                         55 (36.9)                             0.005
  IADL (Independent)           38 (59.4)                         114(76.5)                             0.043
  ASA = 1 or 2                 29 (45.1)                         72 (49.0)                             0.449

**Abbreviations:** ADL, activities of daily living; ASA, American Society of Anesthesiologists scoring system; BFI, Brief Fatigue Inventory ; GDS, Geriatric Depression Scale; IADL, independent activities of daily living; IQR, interquartile; MMS, Mini Mental State; PS, performance status.
